Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Vet Cardiol ; 50: 1-16, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37913604

RESUMO

INTRODUCTION: Cavalier King Charles Spaniels (CKCS) are predisposed to developing myxomatous mitral valve disease (MMVD). Dogs with stage B2 MMVD benefit from medication. OBJECTIVES: To develop (1) breed-specific cut-offs for individual screening tests and (2) predictive models utilizing physical examination (PE), ECG, radiograph, and blood-based biomarker variables in combination for identification of echocardiographic stage B2 MMVD in preclinical CKCS. ANIMALS: Adult, preclinical CKCS not receiving cardiac medications (N = 226). MATERIALS AND METHODS: Prospective, cross-sectional study. Enrolled CKCS underwent PE, ECG, radiography, Doppler blood pressure measurement, echocardiography, and biomarker testing. Dogs were grouped by MMVD stage using echocardiography only. The discriminatory ability of individual tests to identify stage B2 was assessed, and prediction models were developed using variables derived from four 'tests' (PE, ECG, radiography, and biomarkers). RESULTS: N-terminal pro-B-type natriuretic peptide (NT-proBNP) and radiographic vertebral heart size (VHS) had the best discriminatory ability of individual diagnostic tests to differentiate stage A/B1 CKCS from stage B2, with an area under the curve (AUC) of 0.855 and 0.843, respectively. An NT-proBNP ≥1138 pmol/L or a VHS ≥11.5 had high specificity for predicting stage B2 (90.1% and 90.6%, respectively). Prediction models incorporating variables from multiple tests had better discriminatory ability than single tests. The four-test prediction model had an AUC of 0.971. Three and two-test models had AUCs ranging between 0.925-0.959 and 0.895-0.949, respectively. CONCLUSIONS: Both NT-proBNP and VHS have good utility for predicting echocardiographic stage B2 MMVD in CKCS as individual tests. Prediction models incorporating multiple test variables have superior discriminatory ability.


Assuntos
Doenças do Cão , Doenças das Valvas Cardíacas , Cães , Animais , Valva Mitral , Estudos Prospectivos , Estudos Transversais , Doenças do Cão/diagnóstico por imagem , Doenças das Valvas Cardíacas/diagnóstico por imagem , Doenças das Valvas Cardíacas/veterinária , Ecocardiografia/veterinária , Eletrocardiografia/veterinária , Radiografia , Exame Físico , Biomarcadores
2.
Eur J Cancer ; 38(14): 1917-26, 2002 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12204675

RESUMO

Replication-defective adenoviral vectors are currently being employed as gene delivery vehicles for cancer gene therapy. To address the hypothesis that the therapeutic efficacy of adenoviral vectors is restricted by their inability to infect tumour cells expressing low levels of the primary cellular receptor for adenoviruses, the coxsackievirus and adenovirus receptor (CAR), we have employed a pair of ovarian cancer cell lines differing only in the expression of a primary receptor for Ad5. This novel system thus allowed the direct evaluation of the relationship between the efficacy of an adenoviral vector and the primary receptor levels of the host cancer cell, without the confounding influence of other variable cellular factors. We demonstrate that a deficiency of the primary cellular receptor on the tumour cells restricts the efficacy of adenoviral vectors in two distinct cancer gene therapy approaches, TP53 gene replacement therapy and herpes simplex virus thymidine kinase/ganciclovir suicide gene therapy. Moreover, we show that a deficiency of the primary receptor on the tumour cells limits the efficiency of adenovirus-mediated gene transfer in vivo. Since a number of studies have reported that primary cancer cells express only low levels of CAR, our results suggest that strategies to redirect adenoviruses to achieve CAR-independent infection will be necessary to realize the full potential of adenoviral vectors in the clinical setting.


Assuntos
Adenoviridae , Terapia Genética/métodos , Vetores Genéticos/uso terapêutico , Neoplasias Ovarianas/terapia , Adenoviridae/metabolismo , Enterovirus/metabolismo , Feminino , Citometria de Fluxo , Técnicas de Transferência de Genes , Humanos , Neoplasias Ovarianas/metabolismo , Receptores Virais/metabolismo , Células Tumorais Cultivadas
3.
Artigo em Inglês | MEDLINE | ID: mdl-1843489

RESUMO

The safety and efficacy of placing endosseous implants into the anterior mandible at the time of dental extractions with appropriate radical alveolectomies ("immediate implants") is reported. The results were compared to a control group of patients. The success of the immediate group was 92.7%; that of the control group was 98.1%. The difference in success rates was not significant at the P less than .05 level.


Assuntos
Alveolectomia , Implantação Dentária Endóssea/métodos , Prótese Total Imediata , Adulto , Idoso , Distribuição de Qui-Quadrado , Implantes Dentários , Revestimento de Dentadura , Feminino , Humanos , Masculino , Mandíbula , Pessoa de Meia-Idade , Planejamento de Assistência ao Paciente , Fatores de Tempo , Extração Dentária , Resultado do Tratamento
4.
J Prosthet Dent ; 58(1): 69-73, 1987 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-3475462

RESUMO

The predictability of osseointegrated dental implants has revolutionized the combined surgical and prosthodontic care for the partially and totally edentulate patient. Nevertheless, with the proliferation of various types of implant systems, discretion becomes significant. The coordination and communication of the treatment objectives described will provide optimum results. Although the Branemark endosseous implant has been used as the role model, the principles outlined apply to any dental implant system.


Assuntos
Implantação Dentária Endóssea , Equipe de Assistência ao Paciente , Implantação Dentária Endóssea/métodos , Humanos , Relações Interprofissionais , Planejamento de Assistência ao Paciente , Prostodontia , Cirurgia Bucal
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA